



Fungi, the two sides of the same coin




Dr. Yousra A. El-Maradny



PFIDC, City of Scientific Research and Technological Applications, Alexandria, Egypt.

College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Alamein Branch.

Table Of Content

- 
- 01 Beneficial Aspects of Fungi
 - 02 Proteins as small bioactive molecules
 - 03 Lectin as antiviral protein
 - 04 Our lab work
 - 05 Risks and Threats of Fungi
 - 05 Climate Change & Fungal infection

Beneficial Aspects of Fungi

Microorganisms are known as important sources of natural compounds that have been studied and applied for different purposes in distinct areas. Specifically, in the **pharmaceutical** area, fungi have been explored mainly as sources of **antibiotics, antiviral, anti-inflammatory, enzyme inhibitors, hypercholesteremic, anticancer, immunomodulators, and immunosuppressants agents.**



Some Fungal metabolites that have been developed into pharmaceutical products

Metabolite	Source species	Indication(s)
Penicillins G and V	<i>Penicillium rubens</i> , <i>Penicillium chrysogenum</i>	Gram-positive and some Gram-negative bacteria
Cephalosporin C	<i>Acremonium chrysogenum</i>	Gram-positive and some Gram-negative bacteria
Fusidic acid	<i>Acremonium fusidioides</i>	Topical antibiotic for Gram-positive bacterial infections
Griseofulvin	<i>Penicillium griseofulvum</i> , and other <i>Penicillium spp.</i>	Treatment of fungal infections of the skin, hair, and nails
Cyclosporin A	<i>Tolypocladium inflatum</i>	Prevention of organ transplant and tissue graft rejection
Ergotamine	<i>Claviceps purpurea</i> , <i>Claviceps fusiformis</i> , and <i>Claviceps paspali</i>	Vasoconstrictor used as antimigraine agent, also combined with belladonna and phenobarbital for relief from menopausal hot flashes
Ergometrine (ergonovine)	<i>C. purpurea</i> , <i>C. fusiformis</i> , and <i>C. paspali</i>	Treatment of postpartum hemorrhage


Beneficial Aspects of Fungi

Currently, fungal enzymes are accounted for more than 50% of the total enzymes market. This huge market share is largely attributed to a few species of *Aspergillus*, *Trichoderma*, *Rhizopus*, and *Penicillium* genera that fulfill the commercial-scale requirements for enzymes production.


Recently, **mushroom** cultivation has represented a promising competitor in enzymes production in terms of higher productivity and lower invested cost.




Fungal Proteins as small bioactive molecules




Fungal Proteins Anticancer activity



Fungal Proteins Antibacterial activity





Fungal Proteins Antiviral activity





Fungal Lectins Antiviral activity

Lectin is one of the most studied **carbohydrate-binding proteins** from mushroom. About 82% of fungal lectins have been reported from mushrooms, 15% from molds and 3% from yeasts

Lectins are oligomeric widely investigated proteins with unique molecular and physiological characteristics, including diversity in structure, molecular size, metal requirements, glycosylation and carbohydrate specificity.





***In vitro* Assessment of the
Antiviral Activity of Lectin
Extracted from *Pleurotus
ostreatus* Mushroom against
Herpes Simplex Virus and
Hepatitis B virus Infection**

- **Lectins could be used as broad-spectrum antiviral agents rather than the ‘one bug–one drug’ approach.**
- 


```
graph TD; A[Purification and characterization] --> B[Assessment of the cytotoxic effect]; B --> C[Detection of the antiviral activity];
```

Purification and characterization

Assessment of the cytotoxic effect

Detection of the antiviral activity




Mushroom lectins and its Antiviral activity




A



Sample preparation



B) Characterization of lectin



Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*, 72(1-2), 248-254. [https://doi.org/10.1016/0003-2697\(76\)90527-3](https://doi.org/10.1016/0003-2697(76)90527-3)

The characteristic features of the purified lectin (POL)

Purified lectin	Molecular weight (kDa)		HA (HU/ml)	pH stability	Thermostability (°C)	HAI
	SDS-PAGE	Native				
POL	39	80	Human O (4096)	4-9	Up to 40 °C	Fetuin and melibiose



```
graph TD; A[Purification and characterization] --> B[Assessment of the cytotoxic effect]; B --> C[Detection of the antiviral activity];
```

Purification and characterization


Assessment of the cytotoxic effect

Detection of the antiviral activity

II) The cytotoxic effect




II) The cytotoxic effect





Purification and characterization



Assessment of the cytotoxic effect



Detection of the antiviral activity




**III) *In vitro* &
in silico
detection of
antiviral
activity of
POL**



Antiviral activity of POL

HBV

```
graph LR; A[Antiviral activity of POL] --- B[HBV]
```




Cell line



2 hours




Lectin




Virus

1- Investigation of the **anti-HBV** modes of action of lectins



Cell line


HepG2




Virus

HBV

Treatment



Cell line




Virus




**Incubation
then wash** →






Cell line




Virus




Cell line




Lectin



Cell line



Virus





Cell line



Lectin



**CO₂
incubator**




72 h



Lectin


POL






Virus


HBV


Neutralization





**CO₂
incubator**





Cell line


HepG2



Lectin

POL

Blocking



Cell line




Lectin




**Incubation
then wash**







Viral quantification




**DNA
extraction**



q-PCR



**The
antiviral
activity of
POL
against
HBV**



Antiviral activity of POL

HBV

1- Treatment, Neutralization & Blocking

3- viral enzymes (HBV-DDDP)


HSV

Plaques reduction assay

% cell viability (MTT)


Effect of lectin on HBV

DNA-dependent DNA polymerase (DDDP) activity



- The inhibitory capacity of lectin on HBV-DDDP was achieved in enzymatic reaction contained a mixture of virus suspension, lectin and radioactive nucleotide (^3H -thymidine).
- Then the recovered radioactivity were quantified using scintillation counter.

Effect of lectin on **HBV** DNA-dependent DNA polymerase (**DDDP**) activity



Antiviral activity of POL

HBV

1- Treatment, Neutralization & Blocking


3- viral enzymes (HBV-DDDP)

HSV


Plaques reduction assay

% cell viability (MTT)

IV) *In vitro* detection of antiviral activity of POL against HSV




1) Plaques reduction assay




2) Cell viability (MTT)


1) Plaques reduction assay



2) Cell viability % (MTT)





Risks and Threats of Fungi



COVID-19 associated pulmonary aspergillosis (CAPA)

COVID-19 associated pulmonary aspergillosis (CAPA) were reported from China in early 2020. Since then, multiple case series and cohort studies have highlighted the importance of this potentially life-threatening secondary infection, sometimes caused by azole-resistant *Aspergillus* spp. Predominant such as *A. fumigatus*.





02

03


COVID-19 associated mucormycosis (CAM)

COVID-19 associated mucormycosis (CAM) gained worldwide attention in early 2021, during the second wave of the COVID19 pandemic in India. An unprecedented surge of cases of mucormycosis, a fungal infection caused by moulds belonging to the order Mucorales, posed a major healthcare problem with > 47,500 cases reported by the Indian government between May and August 2021. Where *Rhizopus spp.* are predominant.




Invasive Candida infections

Invasive Candida infections in patients with COVID-19 in the intensive care unit (ICU) were first described shortly after the emergence of SARS-CoV-2. Where *C. albicans* are predominant specially *C. auris*



Climate Change Exacerbating Fungal Disease Disparities



Climate Change Exacerbating Fungal Disease Disparities

The increase in **global temperature** has caused disparities in mycoses: the appearance of new pathogens, such as *Candida auris* and *Trichophyton indotineae*, an increase in the **severity** of cases of blastomycosis and dermatophytosis, exacerbation of **allergies**, as well as the appearance of mycoses considered endemic in different non-endemic areas. This situation constitutes a wake-up call to focus efforts on adequately diagnosing and treating these diseases.



References:

- Abdel-Azeem AM, Yadav AN, Yadav N, Usmani Z, editors. Industrially Important Fungi for Sustainable Development: Volume 1: Biodiversity and Ecological Perspectives. Springer International Publishing; 2021 Jun 18.
- Bills GF, Gloer JB. Biologically active secondary metabolites from the fungi. *Microbiology spectrum*. 2016 Nov 4;4(6):4-6.
- Mehela, S., Arzenšek, B., Apostolides, K. Fantastic fungi from Czech forests. *Microbial Biosystems*, 2023; 8(2): 74-79. doi: 10.21608/mb.2023.341713.
- Bonifaz A, García-Salazar E, Frías-De-León MG. Climate Change Exacerbating Fungal Disease Disparities. *Current Fungal Infection Reports*. 2024 Jan 16:1-2.
- Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, Ibrahim AS, Carvalho A. COVID-19-associated fungal infections. *Nature microbiology*. 2022 Aug;7(8):1127-40.
- El-Gendi H, Saleh AK, Badierah R, Redwan EM, El-Maradny YA, El-Fakharany EM. A Comprehensive Insight into Fungal Enzymes: Structure, Classification, and Their Role in Mankind's Challenges. *Journal of Fungi*. 2022; 8(1):23. <https://doi.org/10.3390/jof8010023>.
- El-Maradny YA, El-Fakharany EM, Abu-Serie MM, Hashish MH, Selim HS. Lectins purified from medicinal and edible mushrooms: Insights into their antiviral activity against pathogenic viruses. *International journal of biological macromolecules*. 2021 May 15;179:239-58.



THANK
YOU

Hiph.ymaradny@alexu.edu.eg

Dr. Yousra A. El-Maradny